-
Mashup Score: 0MonumenTAL-1 Results a Pivotal Phase 2 Trial of Talquetamab in RRMM - 11 month(s) ago
Carolina Schinke, MD from the UASM Health provided insights into the MonumenTAL-1 study, focusing on the bispecific antibody talquetamab as a potential treatment option for relapsed/refractory multiple myeloma. Talquetamab has two domains—a GPRC5D-targeting domain for myeloma cells and a CD3 receptor for T-cel…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Examining Cytokine Release Syndrome - 11 month(s) ago
Cytokine release syndrome can limit aggressive RRMM treatment strategies.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In the tenth episode from our #PeerExchange series, "Treatment with Bispecifics in Relapsed-Refractory Multiple Myeloma," a panel of experts discuss how #cytokine release syndrome can limit aggressive #RRMM treatment strategies. Watch here! https://t.co/YX0N2dJE4o https://t.co/WYajgvFbXy
-
-
Mashup Score: 0The RRMM Patient Journey: Part 1 - 12 month(s) ago
Expert panelists discuss considerations for RRMM treatment strategies.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Expert panelists discuss considerations for relapsed / refractory multiple myeloma treatment strategies in part 1, episode 2 of this peer-exchange series titled "Treatment with Bispecifics in Relapsed-Refractory Multiple Myeloma." #RRMM https://t.co/YAswfKO263 https://t.co/p6XGlOvqnm
-
-
Mashup Score: 0
Here, the Multiple Myeloma Hub presents data from an ongoing, open-label, phase I clinical trial investigating ABBV-383 in patients with RRMM.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Catch up with this! #IMS2022 | Want to know more about the efficacy and safety of ABBV-383, a BCMA/CD3 bispecific antibody, for the treatment of patients with #RRMM? Read about the findings from a phase I study here. 👉 https://t.co/ySHNbDmc3r #MMsm https://t.co/PBTcMP4yEQ
-
-
Mashup Score: 0
The phase 3 Karmma-3 trial of ide-cel in patients with triple-class-exposed relapsed/refractory multiple myeloma generated significantly improved progression-free survival and overall response rates vs standard regimens.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with ide-cel led to a significantly prolonged PFS vs standard regimens in patients with triple-class-exposed relapsed and refractory multiple #myeloma. #RRMM #mmsm https://t.co/vgRhQkqrmQ https://t.co/wwii9RcgzZ
-
-
Mashup Score: 1
At a prespecified analysis of the CARTITUDE-1 trial with a median follow-up of approximately 28 months, treatment with cilta-cel continued to elicit positive responses and maintained a favorable risk/benefit profile for patients with multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Updated data from CARTITUDE-1, a phase 1b/2 trial that assessed the safety and efficacy of cilta-cel in heavily pretreated patients with #RRMM, continued to demonstrate early, deep, and durable responses. #mmsm https://t.co/ynHcGSvNHE
-
-
Mashup Score: 0
Results from cohort A of the MagnetisMM–3 trial of erlanatamab for patients with relapsed/refractory multiple myeloma have led the FDA to grant priority review to a biologics license application for the agent in this patient population.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has granted priority review to the BLA of #elranatamab for patients with relapsed/refractory multiple myeloma. #RRMM #mmsm https://t.co/nIfruzXw9r
-
-
Mashup Score: 1
Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.
Source: Oncology Nurse AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The efficacy and safety outcomes associated with idecabtagene vicleucel were similar in a real-world population of patients with R/R #multipleMyeloma. Published in @JCO_ASCO. https://t.co/BDDCUpNNX9 #RRMM
-
-
Mashup Score: 1Real-World Data Shows Wider Reach for Ide-Cel in RRMM - 1 year(s) ago
After the results of the phase 2 KarMMa trial showed that idecabtagene vicleucel is a new standard of care in relapsed/refractory multiple myeloma, a real-world analysis continues to show the CAR T-cell therapy could have a wider reach.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with relapsed/refractory multiple myeloma given ide-cel continued to have a safe and effective response comparable with previous trials, according to a real-world analysis. #mmsm #RRMM https://t.co/sGtyg1TPIJ
-
-
Mashup Score: 0TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results ... - 1 year(s) ago
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in ther…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results - What can this data from a phase 1 study of HPN217 do for patients with RRMM? @Abdallah81MD @KUMedCenter #ASH22 #RRMM Watch and Share the Video Here: https://t.co/cQuqEmuNnh https://t.co/TQ4AHIR4RO
-
🩺 ASCO 2023 Multiple Myeloma 📢 The MonumenTAL-1 study led by #CarolinaSchinke, MD at the @UAMSMyeloma at this year's #ASCO23 sheds light on the potential of #Talquetamab, a bispecific antibody, as a treatment option for #RRMM. 🎯🩸 🔗 https://t.co/1pnSByo8ik https://t.co/s8dE7CENs1